Home » Topics » BioWorld Science

BioWorld Science
RSS

Inflazome divulges new NLRP3 inflammasome inhibitors

March 30, 2021

Adagene reports interim data from ongoing phase I study of ADG-116

March 30, 2021

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Boision present antibodies binding TSLP

March 30, 2021

Phase II trial of IONIS-PKK-LRx as treatment for HAE meets endpoints

March 30, 2021

Lenzilumab improves survival without need for IMV in hospitalized patients with COVID-19

March 30, 2021

Phase IIb study of XF-73 nasal gel meets primary efficacy endpoint

March 30, 2021

FDA and China NMPA clear INDs for JMT-601 in NHL

March 30, 2021

Stragen beings enrollment in phase II trial of STR-324 for postoperative pain

March 30, 2021

Enrollment starts in phase II study of teverelix trifluoroacetate in prostate cancer

March 30, 2021

Phase Ib interim data on CDX-0159 for antihistamine-refractory chronic inducible urticaria

March 29, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...